Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To those who tendered their shares, they have, to date, received a very solid return on their investment.
And this is without the benefit of any of the imminent catalysts promised by NP in the last CC coming to fruition.
One can only imagine what will happen to the SP once we finally get some viable good news.
LM
I agree Z.
I cannot believe that a BOD with this much sophistication and experience will not see the wisdom in bringing in a more experienced CEO when the time is right.
LM
I was surprised and disappointed at the low TO turnout.
I tendered all of my warrants, and thought other Paulson investors would do so as well.
If you believe in the science, getting stock at so low a price seemed like a no brainer to me.
Hopefully, the tendering shareholders will prove to have gotten the deal of the century, and the non-tendering shareholders will kick themselves for not tendering when they had a chance to do so.
LM
We need news, and not promises.
Pourhassan needs to deliver on some of the many promises made in last investor update call.
Had any of those promises been fulfilled, many more investors would likely have tendered their warrants.
Pourhassan's credibility have been irreparably damaged by his repeated unfulfilled promises, and a new leader would be a welcome change.
LM
I share your frustrations about Pourhassan, but remain cautiously optimistic that the science will ultimately prevail.
LM
Hoping you are right, Luv.
My only prediction for the TO is that enough warrants will be tendered that the time to tender will not need to be extended.
I am happy to hear that some Paulson private placement (PRVB) has been a success.
All of my Paulson investments over the past five years have been big losers including Derm Tech, Antria Bio (now RZLT), Zapocharge, Viking Energy (VKIN), and Ammo, Inc. (POWW).
Hoping that Cytodyn turns out to be the one success I have with Paulson.
LM
Rather than bet SP will be $5, Pourhassan should purchase stock while it is still at $0.40.
I am glad Rae is now involved with the deal making.
I was hoping Samsung Biologics, or its parent, would invest given the characterization of leronlim
ab, by its CEO, as a "potential blockbuster. "
One would think some company would be willing to invest given the potential for success, and low stock price.
Given that so many biopharmas with seemingly much less potential get licensing deals or buyouts, it is disappointing that nothing like that has as yet come to fruition.
I remain hopeful, we will one day wake up to read a life changing PR that Cytodyn has been purchased.
LM
The fact that some board members tendered millions of their warrants, and many own millions of shares, was a huge incentive for me to tender my warrants.
Saltz, I never expected to get so deep into this investment, but keep being tantalized by the possible huge upside, and seemingly low price.
I would feel much better if one or more of the non-dilutive financing deals alluded to by NP in the last investor call were to come to fruition. What are you expecting in that regard?
LM
We can build a community doghouse if things go south.
Fingers and toes crossed as we patiently wait for catalysts.
LM
Funny, LM.
I hope she will soon be getting roses and diamonds courtesy of CYDY.
I sure hope we are all right about this investment.
I will feel better when we get some type of non-dilutive financing, or some other catalyst.
LM
Makes sense, BL.
If all goes well, that should make you a very rich ex-lawyer.
LM
I hope and trust we are both right about Cytodyn, BL.
LM
Good luck to us both, gestalt, and to all Cytodyn investors.
If Cytodyn fails, my wife may banish me to my own private island.
LM
Congrats or condolences, depending upon on whether Cytodyn is successful.
I just tendered over 500,000 warrants.
While I share Saltz' confidence, I must confess that having so much tied up in one company, and a clinical stage biopharma at that, makes me just a tad nervous.
Nonetheless, I believe in the end this will end up being a very lucrative investment.
LM
Some type of non-dilutive financing would be the best way to stabilize the SP, and induce fence-sitting warrant holders to tender.
LM
Positive PR could help stabilize, or even increase, the SP, and convince fence-sitting warrant holders to tender prior to June 12.
What is the most likely positive PR we can expect to receive prior to June 12?
LM
Hoping for PR on non-dilutive financing, or other SP moving news, prior to June 12 to get fence-sitting warrant holders off the fence, and tendering their warrants.
I plan to tender my warrants regardless of news, but possibly others are debating whether to tender their warrants.
I feel emboldened by the fact that directors Klump and Welch have tendered over 6 million warrants on the same terms as are now open to Paulson investors, and Cytodyn board members own almost 30 million shares of Cytodyn stock, not including the 27 million shares owned by Dr. Pestell.
It is hard for me to believe that these highly sophisticated board members, with far more knowledge of Cytodyn than me, would risk so much if they were not confident in the eventual success of the company.
LM
Stock options are reported on SEC Form 4.
I am pulling very hard for, and believe very much in, this company.
Although I would prefer a more seasoned CEO, and one with some skin in the game, the science is so compelling that I think this obstacle will be overcome.
The huge commitment by RP, and the substantial investment in the company made by most of the directors, further support my optimism.
Eventually, the battle between the believers and the naysayers will be settled by the FDA that I firmly believe will approve leronlimab for many indications.
LM
It is hard to argue with the facts.
Thanks for your contributions Misiu.
Great "optics" that two directors tendered 17 million warrants on May 8, 2019.
Great optics that six directors collectively own almost 30 million shares.
Yes, it would be great if the CEO had more skin in the game.
However, the directors, who have a LOT of skin in the game are very sophisticated and high powered business entrepreneurs who have all determined, based upon their close-up knowledge of the company, that it is a good investment.
Full disclosure: I am very long, and will be getting longer when I tender warrants.
May I respectfully ask what financial stake you have in this company as your constant barrage of one-sided attacks suggests you are short. Are you?
LM
Options are not shares owned.
Pourhassan owns very few shares, although he has options to purchase many shares in the future at higher valuations than today's SP.
Huge Insider Warrant Tenders + Stock Ownership
As I read the current SEC Form 4 forms (and I could be wrong and, if so, someone please correct me):
Director Michael Klump tendered about 5.34 million warrants that had exercise prices of between $0.30 and $1.35, and expired between 2021 and 2023.
Klump and his company, Argonne Trading, now own over 12 million shares of Cytodyn stoick.
Director David Welch tendered about 1.65 million warrants that had an exercise price of $0.75, and expired between 2021 and 2023.
Welch and his company, LFRA, LLC, now own over 3 million shares of Cytodyn stock.
Director Jordan Navdenov has no warrants to tender (as he owns only stock options), but owns over 5.3 million shares of Cytodyn stock.
Director Scott Kelly has no warrants to tender (as he owns only stock options), but owns over 1.24 million shares of Cytodyn stock.
Director Carl Dockery has no warrants to tender (as he owns only stock options), but owns over 7.57 million shares of Cytodyn stock.
CEO Nader Pourhassan has no warrants to tender (as he owns only stock options), and (together with his wife) owns 177,239 shares of Cytodyn stock.
I find it encouraging that two directors tendered 7 million warrants, on the same terms as are being offered to the Paulson investors.
I find it even more encouraging that the directors as a whole have a huge amount of skin in the game.
LM
There are many possible catalysts of which TNBC is one.
Favorable interim data from the TNBC study could blow the roof off the SP, as could good mono data.
A heavy warrant tender, sale of the prostrate test, or non-dilutive financing, would greatly help the cause as well.
Best of luck.
LM
I doubt my posts have any influence on SP, and truly hope they do not.
Everyone has to decide his or her own level of commitment, and tolerance for risk.
Like any clinical stage biopharma, CYDY is very risky, but has huge upside.
For me, personally, I think the potential reward justifies the risk as leronlimab has already proven itself to be safe and effective in a number of HIV clinical trials.
Leronlimab could also prove to be safe and effective for other indications, which if so, will make CYDY even more valuable.
If I am right, today's CYDY investors will do very well, just as investors in other successful clinical stage biopharmas have done in the past.
If I am wrong, I will take my lumps just as investors in other unsuccessful clinical stage biopharmas have done in the past.
Either way, I am satisfied that I have done sufficient due diligence to justify upping the ante by tendering all of my warrants, while holding all of my stock.
GLTU in this and all of your other investments.
LM
If interim results show leronlimab has a positive effect in controlling TMBC, CYDY's SP will go through the roof, and BP will be lining up to buy the company.
These interim results will obviously be announced much sooner than the trial completion date, and could come within the next few months.
We are in very good hands with Dr. Pestell in charge of this clinical trial.
LM
Best of luck to you as well misiu.
LM
Trading:
From your lips...
LM
Trading:
Way too much math for me.
I barely passed basis math in HS.
For me, it's a leap of faith.
You either believe in lironlimab, or you don't.
If lironlimab proves to be a successful drug for HIV, or any of the other indications for which it is being tested, a few pennies per share either way will be inconsequential.
That's my thinking anyway, and the reason I am tendering my warrants, and holding my shares.
LM
Zuess:
Hopefully, we will all be rewarded for backing CYDY.
LM
Index Guy:
You have to do what makes sense for you based on your own situation.
GLTU on CYDY, and on all of your investments.
LM
Thanks sjacobs.
Good luck to all of us investors, and the patients I hope will someday be helped by leronlimab.
LM
Thanks misiu.
I enjoy reading, and greatly appreciate, your posts on the other board.
LM